Navigation Links
QRxPharma Initiates Second Comparative Study for MoxDuo(TM) IR Dual-Opioid(TM) Pain Therapy
Date:2/19/2009

Efficacy and Safety Study in Patients with Severe Post-Operative Pain; Data to Serve as Predictor of Clinical Benefits and Support NDA Submission

SYDNEY and BEDMINSTER, N.J., Feb. 19 /PRNewswire-FirstCall/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY), a clinical-stage specialty pharmaceutical company focused on the development and commercialisation of therapies for pain and central nervous system (CNS) disorders, announced today the initiation of a comparative 3-arm pilot study to evaluate the analgesic efficacy and safety profile of MoxDuo(TM) IR (immediate release) capsules in patients who have undergone total knee replacement surgery. Data from this study will be used to further establish the optimal dose regimen for MoxDuo(TM) IR, select an appropriate control group, and properly design an upcoming pivotal Phase 3 trial in patients following total knee replacement surgery. The company expects to complete dosing in April 2009 and is on track to launch MoxDuo(TM) IR in the US marketplace in 2011. Specifically, MoxDuo(TM) IR targets the acute pain market, a $2.5 billion segment of the $7 billion spent annually on prescription opioids in the US.

"This study represents an important step forward as the data collected will not only provide critical insights for structuring Phase 3 trials leading to product approval, but also serve as an important indicator of the clinical and commercial value MoxDuo(TM) IR offers," said Dr. John Holaday, Managing Director and Chief Executive Officer, QRxPharma. "Doctors are looking for new ways to manage the treatment of severe post-operative pain. We anticipate that QRxPharma's patented MoxDuo(TM) IR will greatly improve patient care by providing equal or better analgesia with fewer and less intense side effects than the current standards of care."

In this clinical trial, each group of patients experiencing moderate to severe postoperative pain following total knee r
'/>"/>

SOURCE QRxPharma Limited
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. QRxPharma Initiates Comparative Study for MoxDuoIR(TM) Dual-Opioid(TM) Pain Therapy
2. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
3. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
4. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
5. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
6. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
7. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
8. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
9. GeneNews initiates patient sample accrual for validation studies of colon cancer blood test
10. Human Genome Sciences Initiates Second Randomized Phase 2 Trial of HGS-ETR1 in Combination With Chemotherapy
11. Conatus Pharmaceuticals Initiates a Phase 2 Clinical Trial for the Treatment of Hepatitis

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)...RNewswire/ -- Reportlinker.com announces that a ne...ogue: ,, Carbondioxide Incubators - A Global M...com/p0164368/Carbondioxide-Incubators---A-Global-M...most critical equipment used in microbiology, gene... providing a controlled environment to grow and st...
(Date:12/2/2009)...swire/ -- The world,s first concept demonstration ...hrough alternative to replace a petrochemically pr...rubber with renewable biomass, made their debut in...on display at a lounge in the common departure are...ut December 21, while the other tire will make app...
(Date:12/2/2009)...cember 2 , - "Bolstering ...itage" , Coinciding with the Internationa... Republic is hosting an international conference i...biological resources in Africa. The,conference wil...isters,scientific experts, private companies, rep...
(Date:12/2/2009)...el, December 2 Gamida Cell announc...nical (animal study) safety and,efficacy of a gene...ill,Cornell Medical College and Gamida Cell. The p...as such as Cooley,s Anemia. , Gamida Cell... ex vivo,populations of stem/progenitor cells. Th...
Breaking Biology Technology:Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 2Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 3Reportlinker Adds Carbondioxide Incubators - A Global Market Perspective 4The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 2The World's First Goodyear Concept Tires Made with BioIsoprene(TM) Technology Arrive in Copenhagen in time for United Nations Climate Change Conference 3Libreville International Conference 2-3 June 2010 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 3
...EHOVOT, Israel and JERSEY CITY, New Jersey, Decemb...,innovative molecular diagnostic company leveragin...lidated financial results for the quarter ended,Se...The company recorded revenues for the third quarte...d from the date of acquisition of Parkway Clinical...
...AN DIEGO, Dec. 4 Favrille, Inc.,(OTC Bulletin Boa...a health,information company focused on secure Web...ds (PHRs), announced today that two significant co...ive merger agreement have been met. , (Logo:...F521LOGO ) , "We are pleased to announce tha...
...ORT LAUDERDALE, Fla., Dec. 4 Imaging Diagnostic,S...r in laser optical breast,imaging, announced today...,adjunct to mammography is featured in the Decembe... http://www.newscom.com/cgi-bin/prnh/20040412/IM...ist at Charite Hospital in Berlin,Germany, authore...
Other Biology Technology:Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 2Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 3Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 4Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 5Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 6Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 7Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 8Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 9Rosetta Genomics Reports Third Quarter 2008 Financial Results; Records First Revenues of $705,000; $7.4 Million Added to Available Cash Due to Repurchase of ARS 10Favrille and MyMedicalRecords.com, Inc. Obtain Shareholder Approval to Move Forward With Merger 2Favrille and MyMedicalRecords.com, Inc. Obtain Shareholder Approval to Move Forward With Merger 3Favrille and MyMedicalRecords.com, Inc. Obtain Shareholder Approval to Move Forward With Merger 4Favrille and MyMedicalRecords.com, Inc. Obtain Shareholder Approval to Move Forward With Merger 5Imaging Diagnostic Systems CT Laser Mammography (CTLM) Technology Featured in Peer-Reviewed Journal 2
(Date:12/3/2009)...., Dec. 3 BIO-key Intern... in wireless public safety and finger-based biomet...ority of its shareholders at a Special Shareholder...ny,s Law Enforcement Division to Interact911 Mobil...t in favor and 1.2% were opposed. ,, (Logo: ht...
(Date:12/3/2009)...s or solar panels that repels grime and dirt? Expa...ric car? New Tel Aviv University research, just pu...kthrough in assembling peptides at the nano-scale ...e true in just a few years. , Operating in the r... meter) and even smaller, graduate student Lihi Ad...
(Date:12/3/2009)...Dec. 3, 2009) Van Andel Research Institute (VAR...lant hormone abscisic acid (ABA) works at the mole...l stresses such as drought and cold. Their findin...engineer crops that thrive in harsh environments a... The findings could also have implications for str...
Breaking Biology News(10 mins):BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3A window that washes itself? 2VAI researchers find long awaited key to creating drought resistant crops 2VAI researchers find long awaited key to creating drought resistant crops 3Insmed Provides Update on Supply of IPLEX 28TM 29 52763 1Insmed Provides Update on Supply of IPLEX 28TM 29 52763 2Insmed Provides Update on Supply of IPLEX 28TM 29 52763 3Questcor and Child Neurology Foundation Announce Creation of Infantile Spasms Awareness Week 52759 1Questcor and Child Neurology Foundation Announce Creation of Infantile Spasms Awareness Week 52759 2Questcor and Child Neurology Foundation Announce Creation of Infantile Spasms Awareness Week 52759 3Questcor and Child Neurology Foundation Announce Creation of Infantile Spasms Awareness Week 52759 4S C Medical Home Pilot for Diabetes Enrolls 1 110 4781 1S C Medical Home Pilot for Diabetes Enrolls 1 110 4781 2S C Medical Home Pilot for Diabetes Enrolls 1 110 4781 3
...tes and other nations commit to the path of biofue...r sustainable practices in an industry that will, ...Earth,s landscape in a significant way." , In a p...gazine, Melillo and 22 co-authors call for science...stry, which by 2050 could command as much land as ...
...ne for neuroblastoma and melanoma developed by s...edical Center in collaboration with investigators...t impact on tumor growth in mice, according to new...research journal Cancer Immunology, Immunotherapy...uce an immune system response, allowing for a pers...
...er ) show a highly selective behavior towards odor...at a single olfactory stimulus is often not suffic...urces or oviposition sites. Interestingly, the beh...er varieties, so-called "wildtypes". Natural odor...whereas artificial flavors induced a more differen...
Other Biology News:Thinking it through: Scientists call for policy to guide biofuels industry toward sustainability 2Thinking it through: Scientists call for policy to guide biofuels industry toward sustainability 3Children's National researchers develop novel anti-tumor vaccine 2What is wild? Odor attraction among different wildtype Drosophila 2What is wild? Odor attraction among different wildtype Drosophila 3
Bovine Albumin from Bovine Serum, BODIPY FL conjugated/tagged from Molecular Probes (Invitrogen)
Protein Expression Service (Insect cell) from Exon BioSystems
Bovine Albumin from Bovine Serum, Fluorescein conjugated/tagged from Molecular Probes (Invitrogen)
Goat Anti-Human PARAINFLUENZA VIRUS 2+3 Polyclonal Antibody, Unconjugated from AbD Serotec
Biology Products: